blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1492811

EP1492811 - MUTEINS OF THE C5A ANAPHYLATOXIN, NUCLEIC ACID MOLECULES ENCODING SUCH MUTEINS, AND PHARMACEUTICAL USES OF MUTEINS OF THE C5A ANAPHYLATOXIN [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  27.07.2012
Database last updated on 13.11.2024
Most recent event   Tooltip30.05.2014Lapse of the patent in a contracting state
New state(s): LU		published on 02.07.2014  [2014/27]
Applicant(s)For all designated states
Cincinnati Children's Hospital Medical Center
3333 Burnet Avenue, MLC 7021
Cincinnati, OH 45229-3039 / US
[N/P]
Former [2005/01]For all designated states
Cincinnati Childrens's Hospital Medical Center
3333 Burnet Avenue, MLC 7021
Cincinnati, OH 45229-3039 / US
Inventor(s)01 / OTTO, Magnus
Halberstadtweg 9
30659 Hannover / DE
02 / KÖHL, Jörg Cincinnati Childr. Hospital Med.Center
Dev.of Molecul. Immunology
3333Burnet Av. MLC 7021
Cincinnati, OH 45229-3039 / US
 [2011/38]
Former [2005/01]01 / OTTO, Magnus
Halberstadtweg 9
30659 Hannover / DE
02 / KÖHL, Jörg Cincinnati Childr. Hospital Med.Center
Dev.of Molecul. Immunology 3333Burnet Av. MLC 7021
Cincinnati, OH 45229-3039 / US
Representative(s)Viering, Jentschura & Partner mbB Patent- und Rechtsanwälte
Grillparzerstrasse 14
81675 München / DE
[N/P]
Former [2012/33]Viering, Jentschura & Partner
Grillparzerstrasse 14
81675 München / DE
Former [2011/38]Schiweck, Wolfram
Viering, Jentschura & Partner Postfach 22 14 42
80504 München / DE
Former [2005/01]Schiweck, Wolfram, Dr.
Viering, Jentschura & Partner Patent- und Rechtsanwälte Steinsdorfstrasse 6
80538 München / DE
Application number, filing date02807051.419.03.2002
[2005/01]
WO2002EP03035
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO03078457
Date:25.09.2003
Language:EN
[2003/39]
Type: A1 Application with search report 
No.:EP1492811
Date:05.01.2005
Language:EN
The application published by WIPO in one of the EPO official languages on 25.09.2003 takes the place of the publication of the European patent application.
[2005/01]
Type: B1 Patent specification 
No.:EP1492811
Date:21.09.2011
Language:EN
[2011/38]
Search report(s)International search report - published on:EP25.09.2003
ClassificationIPC:C07K14/47, C12N15/12, A61K38/17, C12N1/15, C12N1/21, C12N1/19, C12N5/16, C12N15/62
[2005/01]
CPC:
C07K14/472 (EP,US); A61P29/00 (EP); A61P43/00 (EP);
A61K38/00 (EP,US)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   TR [2005/01]
TitleGerman:MUTEINE DES C5A ANAPHYLATOXINS, FÜR SOLCHE MUTEINE KODIERENDE NUKLEINSÄUREMOLEKÜLE, SOWIE PHARMAZEUTISCHE VERWENDUNGEN VON MUTEINEN DES C5A ANAPHYLATOXINS[2005/01]
English:MUTEINS OF THE C5A ANAPHYLATOXIN, NUCLEIC ACID MOLECULES ENCODING SUCH MUTEINS, AND PHARMACEUTICAL USES OF MUTEINS OF THE C5A ANAPHYLATOXIN[2005/01]
French:MUTEINES D'ANAPHYLATOXINE C5A, MOLECULES D'ACIDES NUCLEIQUES CODANT POUR CES MUTEINES ET UTILISATIONS PHARMACEUTIQUES DES MUTEINES D'ANAPHYLATOXINE C5A[2005/01]
Entry into regional phase01.10.2004National basic fee paid 
01.10.2004Designation fee(s) paid 
01.10.2004Examination fee paid 
Examination procedure01.10.2004Amendment by applicant (claims and/or description)
01.10.2004Examination requested  [2005/01]
28.11.2006Despatch of a communication from the examining division (Time limit: M06)
25.05.2007Reply to a communication from the examining division
11.08.2008Despatch of a communication from the examining division (Time limit: M06)
17.02.2009Reply to a communication from the examining division
22.10.2009Despatch of a communication from the examining division (Time limit: M06)
27.04.2010Reply to a communication from the examining division
18.06.2010Despatch of a communication from the examining division (Time limit: M04)
19.08.2010Reply to a communication from the examining division
14.03.2011Communication of intention to grant the patent
07.07.2011Fee for grant paid
07.07.2011Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  28.11.2006
Opposition(s)22.06.2012No opposition filed within time limit [2012/35]
Fees paidRenewal fee
01.10.2004Renewal fee patent year 03
31.03.2005Renewal fee patent year 04
29.03.2006Renewal fee patent year 05
28.03.2007Renewal fee patent year 06
27.03.2008Renewal fee patent year 07
26.03.2009Renewal fee patent year 08
25.03.2010Renewal fee patent year 09
28.03.2011Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT21.09.2011
BE21.09.2011
CY21.09.2011
DK21.09.2011
FI21.09.2011
IT21.09.2011
SE21.09.2011
TR21.09.2011
GR22.12.2011
ES01.01.2012
PT23.01.2012
IE19.03.2012
LU19.03.2012
MC31.03.2012
[2014/27]
Former [2014/21]AT21.09.2011
BE21.09.2011
CY21.09.2011
DK21.09.2011
FI21.09.2011
IT21.09.2011
SE21.09.2011
TR21.09.2011
GR22.12.2011
ES01.01.2012
PT23.01.2012
IE19.03.2012
MC31.03.2012
Former [2013/22]AT21.09.2011
BE21.09.2011
CY21.09.2011
DK21.09.2011
FI21.09.2011
IT21.09.2011
SE21.09.2011
GR22.12.2011
ES01.01.2012
PT23.01.2012
IE19.03.2012
MC31.03.2012
Former [2013/08]AT21.09.2011
BE21.09.2011
CY21.09.2011
DK21.09.2011
FI21.09.2011
IT21.09.2011
SE21.09.2011
GR22.12.2011
PT23.01.2012
IE19.03.2012
MC31.03.2012
Former [2012/47]AT21.09.2011
BE21.09.2011
CY21.09.2011
DK21.09.2011
FI21.09.2011
IT21.09.2011
SE21.09.2011
GR22.12.2011
PT23.01.2012
MC31.03.2012
Former [2012/35]AT21.09.2011
BE21.09.2011
CY21.09.2011
DK21.09.2011
FI21.09.2011
IT21.09.2011
SE21.09.2011
GR22.12.2011
PT23.01.2012
Former [2012/23]AT21.09.2011
BE21.09.2011
CY21.09.2011
FI21.09.2011
IT21.09.2011
SE21.09.2011
GR22.12.2011
PT23.01.2012
Former [2012/18]AT21.09.2011
BE21.09.2011
CY21.09.2011
FI21.09.2011
SE21.09.2011
GR22.12.2011
Former [2012/12]AT21.09.2011
CY21.09.2011
FI21.09.2011
SE21.09.2011
GR22.12.2011
Former [2012/11]AT21.09.2011
FI21.09.2011
SE21.09.2011
GR22.12.2011
Former [2012/10]FI21.09.2011
SE21.09.2011
GR22.12.2011
Former [2012/09]FI21.09.2011
Cited inInternational search[XD]  - HENNECKE M., "Untersuchung zur C5a-C5a Rezeptor-Interaktion unter Verwendung des Phage-Displays", PHD THESIS, Medical School Hannover, (1998), XP002210870 [XD] 1-32 * page 95, paragraph 6.5; table 18 * * page 99; table 21 * * page 122 - page 126 *
 [X]  - HELLER T ET AL, "A C5A mutant selected from a phage library is a potent C5A-receptor antagonist in vitro and in vivo.", MOLECULAR IMMUNOLOGY, XVII International Complement Workshop;Rhodes, Greece; October 11-16, 1998, (199804), vol. 35, no. 6-7, ISSN 0161-5890, page 365, XP001098701 [X] 1-32 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0161-5890(98)90670-8
 [DX]  - HELLER T ET AL, "Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 15 JUL 1999, (19990715), vol. 163, no. 2, ISSN 0022-1767, pages 985 - 994, XP002210871 [DX] 1-32 * abstract * * discussion *
 [DX]  - HENNECKE MEIKE ET AL, "A detailed analysis of the C5a anaphylatoxin effector domain: Selection of C5a phage libraries on differentiated U937 cells.", EUROPEAN JOURNAL OF BIOCHEMISTRY, (199802), vol. 252, no. 1, ISSN 0014-2956, pages 36 - 44, XP002164193 [DX] 1-32 * page 42, column 2, line 30 - page 43, paragraph L; table 3 *

DOI:   http://dx.doi.org/10.1046/j.1432-1327.1998.2520036.x
 [A]  - PELLAS T C ET AL, "Novel C5a receptor antagonists regulate neutrophil functions in vitro and in vivo.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 1 JUN 1998, (19980601), vol. 160, no. 11, ISSN 0022-1767, pages 5616 - 5621, XP002210872 [A] 16,17 * abstract * * page 5620, column 1, paragraph 3 *
 [A]  - TOTH MATTHEW J ET AL, "The pharmacophore of the human C5a anaphylatoxin.", PROTEIN SCIENCE, (1994), vol. 3, no. 8, ISSN 0961-8368, pages 1159 - 1168, XP001098679 [A] 1-32 * abstract * * page 1164; table 1 *
 [A]  - ANDERSON CY ET AL, "C5aR ligand peptide 3D QSAR study performed with an applied linear conformation.", JOURNAL OF PEPTIDE RESEARCH, (1997), vol. 49, no. 6, ISSN 1397-002X, pages 476 - 483, XP000657589 [A] 1-32 * table 3 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.